Results from the phase 3 NIAGARA trial led to the approval of adjuvant durvalumab/chemotherapy for patients with muscle-invasive bladder cancer after radical cystectomy.
Ariana Pelosci
Advertisement
Ariana Pelosci, assistant managing editor for CancerNetwork® and the journal ONCOLOGY®, has been with the team since June 2021. She specializes in both web and print, and runs the social media accounts for CancerNetwork®.
She graduated from the University of Delaware, where she studied Media Communications and minored in journalism and marketing. At heart, she is a Jersey girl, and you can always find her down the shore during her free time.
Ariana loves to read, specifically historical or contemporary fiction. Follow Ariana on Twitter @APelosci or email her at apelosci@mjhlifesciences.com.
Articles by Ariana Pelosci
At 5 years, 100% of patients with breast cancer who did not receive surgery had ipsilateral breast tumor relapse-free survival.
Data from the phase 3 CABINET study support the approval of cabozantinib in patients with pancreatic and extra-pancreatic neuroendocrine tumors.
The new drug application for TLX007-CDx has been approved by the FDA for patients with prostate cancer.
Christina Henson, MD, discusses recent phase 3 trial results comparing durvalumab to cetuximab in head and neck cancer, and why the trial was stopped early.
Results from the NIRVANA-R trial found niraparib/bevacizumab maintenance yielded positive activity in pretreated ovarian cancer.
The phase 2 trial is currently accruing additional patients with advanced mesonephric gynecologic cancer for treatment with avutometinib/defactinib.
The KEYLYNK-001 trial found improved PFS among patients with advanced ovarian cancer given pembrolizumab/olaparib.
Second interim analysis results from the KEYNOTE-A18 trial show continued efficacy of pembrolizumab/CCRT in those with locally advanced cervical cancer.
Learn how COVID-19 impacted oncology practice from the uptake of telehealth to delays in screening, with key takeaways from leading oncologists.
The trial was terminated early due to no statistical significance observed between durvalumab and cetuximab for patients with head and neck squamous cell carcinoma.
A multidisciplinary care approach should be utilized when discussing sexual health with survivors of breast cancer.
For International Women's Day, CancerNetwork highlights impactful oncology research on topics from rising health care costs to innovative treatments.
As a gynecologic oncology surgeon, Mario M. Leitao, MD, FACOG, FACS, highlights how his career has evolved through using robotic surgery, new fertility preservation techniques, and his contributions to the research field.
Median PFS and OS were comparable between age groups when CAR T-cell therapy was given as treatment for patients with relapsed/refractory LBCL.
Scarlett Lin Gomez, MPH, PhD, highlights facts from her research that are impacting cancer disparities and how she is finding ways to improve them.
A team from the University of Munich analyzed HRQOL outcomes in rural/urban patients with bladder cancer and after ADT treatment and postoperative radiotherapy in prostate cancer.
Efficacy results remained consistent with previous reports in the cabozantinib, nivolumab, and ipilimumab arm for patients with advanced renal cell carcinoma.
Aditya Bardia, MD, discusses the FDA approval of T-DXd for HER2-low or ultralow metastatic breast cancer and its potential impact on treatment paradigms.
Options like acupuncture or cannabis use may be viable to help manage symptoms related to gastrointestinal cancer treatment.
A phase 2 trial found T-DM1 to be a tolerable treatment option for patients with HER2-positive biliary tract adenocarcinoma.
Results from the DESTINY-Breast06 trial led to the approval of T-DXd for patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer.
A pCR rate of 44% was observed when neoadjuvant pembrolizumab was given to patients with dMMR colon cancer.
Results from the ACCELERATE trial did not improve relapse-free survival when chemoradiation was added to chemotherapy for patients with resected gallbladder cancer.
Results from the phase 3 LAPIS trial showed pamrevlumab/chemotherapy did not improve survival vs placebo/chemotherapy in locally advanced, unresectable pancreatic cancer.
Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Results from the phase 2 FDZL-001 trial showed high OS and PFS rates when camrelizumab plus Nab-POF was used to treat patients with gastric/GEJ cancer.
Results from the CodeBreaK 300 trial helped lead to the approval of sotorasib/panitumumab in KRAS G12C-mutated CRC.
The FDA has approved acalabrutinib in previously untreated MCL based on results from the phase 3 ECHO trial.
Data from CheckMate-67T support the approval of subcutaneous nivolumab in patients with solid tumors across all previously approved nivolumab indications.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Updated Cosibelimab Label in Cutaneous Squamous Cell Carcinoma
2
Subcutaneous Toripalimab Meets Primary End Points in Nonsquamous NSCLC
3
Zanidatamab Shows Meaningful Benefit in HER2+ Biliary Tract Cancer
4
ONCOLOGY Editorial Advisory Board Member Dies from Glioblastoma
5
